Cargando…

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

INTRODUCTION: Circulating tumor cells (CTC) have been recently proposed as a new dynamic blood marker whose positivity at baseline is a prognostic factor and whose changes under treatment are correlated with progression-free survival (PFS) in metastatic breast cancer patients. However, serum marker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bidard, François-Clément, Hajage, David, Bachelot, Thomas, Delaloge, Suzette, Brain, Etienne, Campone, Mario, Cottu, Paul, Beuzeboc, Philippe, Rolland, Emilie, Mathiot, Claire, Pierga, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496147/ https://www.ncbi.nlm.nih.gov/pubmed/22330883 http://dx.doi.org/10.1186/bcr3114

Ejemplares similares

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
por: Cabel, Luc, et al.
Publicado: (2021)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
por: Bidard, François-Clément, et al.
Publicado: (2013)

Circulating tumor cells in breast cancer
por: Bidard, Francois-Clement, et al.
Publicado: (2016)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

Clinical utility of circulating tumor cells: an update
por: Vasseur, Antoine, et al.
Publicado: (2020)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
por: Darrigues, Lauren, et al.
Publicado: (2021)

Circulating Tumor Cells in Early Breast Cancer
por: Thery, Laura, et al.
Publicado: (2019)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study
por: Callens, Céline, et al.
Publicado: (2021)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
por: Berger, Frédérique, et al.
Publicado: (2022)

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients
por: Cabel, Luc, et al.
Publicado: (2019)

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
por: Sabatier, Renaud, et al.
Publicado: (2021)

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification
por: Reyal, Fabien, et al.
Publicado: (2012)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
por: Bidard, François-Clément, et al.
Publicado: (2019)

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
por: Darlix, Amélie, et al.
Publicado: (2019)

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
por: Bidard, François-Clément, et al.
Publicado: (2012)

Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals
por: Chalumeau, Clelia, et al.
Publicado: (2022)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Impact of body mass index on overall survival in patients with metastatic breast cancer
por: Saleh, Khalil, et al.
Publicado: (2020)

Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer
por: Carbonnier, Vincent, et al.
Publicado: (2023)

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer
por: Ligthart, Sjoerd T., et al.
Publicado: (2013)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
por: Alhenc-Gelas, Marion, et al.
Publicado: (2021)

COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)
por: Gligorov, Joseph, et al.
Publicado: (2020)

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
por: Vuagnat, Perrine, et al.
Publicado: (2020)

Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer
por: Giudici, Fabiola, et al.
Publicado: (2023)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort
por: Antoine, Alison, et al.
Publicado: (2023)

A DNA methylation-based liquid biopsy for triple-negative breast cancer
por: Cristall, Katrina, et al.
Publicado: (2021)

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
por: Grinda, T., et al.
Publicado: (2021)

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
por: Vincent-Salomon, A, et al.
Publicado: (2008)

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
por: Courtinard, Coralie, et al.
Publicado: (2023)

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
por: Tulukcuoglu Guneri, Ezgi, et al.
Publicado: (2022)

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
por: Frank, Sophie, et al.
Publicado: (2020)

Impact de l’épidémie de COVID-19 sur les demandes de prise en charge initiale pour cancer du sein
por: Héquet, Delphine, et al.
Publicado: (2020)

Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system
por: Feunteun, Jean, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_is9v4vehtsganoupp5rdg6075q